ILONOV
Preclinical-stage biopharmaceutical spin-off from the European Diabetes Study Center developing first-in-class myokine-based biotherapies for diabetes and metabolic diseases. The company focuses on discovery and preclinical development of muscle-secreted hormones (myokines) to restore metabolic balance, protect pancreatic islets and improve outcomes of beta-cell replacement therapies.
Industries
Nr. of Employees
small (1-50)
ILONOV
BD Rene Leriche, 67200 Strasbourg, France
Products
Myokine‑based biologic candidate (lead)
A preclinical myokine‑derived biologic candidate developed to restore metabolic balance, protect pancreatic islets from inflammation and improve outcomes of beta‑cell replacement therapies.
Myokine‑based biologic candidate (lead)
A preclinical myokine‑derived biologic candidate developed to restore metabolic balance, protect pancreatic islets from inflammation and improve outcomes of beta‑cell replacement therapies.
Services
Collaborative research and preclinical development arrangements with academic and industry partners to advance discovery and lead selection of myokine‑based therapeutics.
Collaborative research and preclinical development arrangements with academic and industry partners to advance discovery and lead selection of myokine‑based therapeutics.
Expertise Areas
- Myokine discovery and translational research
- Preclinical therapeutic development for diabetes
- Islet biology and beta‑cell protection
- Preclinical efficacy testing in diabetic animal models
Key Technologies
- Myokine‑based biologics
- Human primary skeletal muscle cell libraries
- In vivo diabetes animal models
- Beta‑cell/islet functional assays
News & Updates
Joined an accelerator portfolio and signed a research collaboration with a pharmaceutical partner to advance lead selection and explore myokine biology.
Company representatives exhibited and met partners at Biofit 2025 in Strasbourg (Booth F39).
Company participation in events including Trinational Healthtech Days, Joslin Diabetes Symposium, EASD Annual Meeting, Festival of Biologics and Bio€quity between 2023–2025.
Launch of an 18‑month R&D program supported by a regional/national investment program to advance preclinical development of the lead myokine candidate and explore additional indications.
Selection for the Prix Galien France award recognizing therapeutic innovation for work on the muscle secretome and its therapeutic potential in diabetes.
Awarded pre‑seed funding and recognized by an early‑stage innovation competition; obtained DeepTech labelling and pre‑seed support from public programs.
Joined an accelerator portfolio and signed a research collaboration with a pharmaceutical partner to advance lead selection and explore myokine biology.
Company representatives exhibited and met partners at Biofit 2025 in Strasbourg (Booth F39).
Company participation in events including Trinational Healthtech Days, Joslin Diabetes Symposium, EASD Annual Meeting, Festival of Biologics and Bio€quity between 2023–2025.
Launch of an 18‑month R&D program supported by a regional/national investment program to advance preclinical development of the lead myokine candidate and explore additional indications.
Selection for the Prix Galien France award recognizing therapeutic innovation for work on the muscle secretome and its therapeutic potential in diabetes.
Awarded pre‑seed funding and recognized by an early‑stage innovation competition; obtained DeepTech labelling and pre‑seed support from public programs.